Radiopharmaceuticals Market Global Scenario, Market Size, Outlook, Trend, and Forecast, 2016 – 2025

Global Radiopharmaceuticals Market size is projected to be valued $XX Billion by 2024; with a CAGR of XX% from 2017 to 2025. A radiopharmaceutical is made up of two components that are drug component and radioactive component. This radioactive component consists of radioistopes which emits gamma rays which help in diagnostic. Radiopharmaceutical has been used effectively for cancer cell destruction, pain treatment in palliative care for bone cancer or arthritis. Radiopharmacology is useful several branches of medicine including cardiology, nephrology, oncology, gastroenterology, immunology, and neurology.



The growth of global radiopharmaceutical market is attributed to the factors such as increase in the number of patients of cancer, dementia and Alzhimer’s Parkinson and increase in demand from developing countries attributed to non-invasiveness procedures. Moreover factors such as advances in radiotracers are also fueling the growth of global radiopharmaceutical market. However, side effects due to consumption of high doses and stringent regulatory guidelines restraints the growth of market.

The global radiopharmaceuticals market is segmented on the basis of product type, application and geography. On the basis on product type the market is segmented into diagnostic and therapeutic products. Diagnostic products market is further classified into SPECT and PET isotopes. Therapeutics market segment is further classified alpha emitters, beta emitters, and brachytherapy. On the basis of application market is segmented into cardiology, neurology, oncology, thyroid, bone metastasis, and endocrine tumors. Geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and rest of the world (RoW).

Some of themajor companies in global radiopharmaceuticals market are Bayer Healthcare AG, IBA Molecular Imaging, Mallinckrodt plc., Sigma Aldrich Corporation, Medtronic plc, Nordien, Inc., Jubilant Pharma, Cardinal Health, Inc., GE Healthcare, Eczacibasi-Monrol Nuclear Products, and Siemens Healthcare.

The report covers

  • The detailed analysis of Radiopharmaceuticals Market with respect to key segments such as product type and application has been included in the report
  • The report comprises the qualitative and quantitative analysis of the market with market estimation over 2016 – 2025 and CAGR between 2017 and 2025
  • Comprehensive analysis of market dynamics including growth factors, restraining factors and opportunities will be provided in the report
  • An exhaustive regional and country wise analysis of Radiopharmaceuticals Market has been covered in the report
  • Profile of the major key players operating in the Radiopharmaceuticals Market will be provided, with detailed study on their key financials, product & services, new developments and business strategies

Scope of the Global Radiopharmaceuticals Market

Product Type Segments

  • Diagnostic
    • SPECT
    • PET isotopes
  • Therapeutic
    • Classified alpha emitters
    • Beta emitters
    • Brachytherapy

Application Segments

  • Cardiology
  • Neurology
  • Oncology
  • Thyroid
  • Bone metastasis
  • Endocrine tumors

Geography Segments

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Others
  • RoW
    • South America
    • Middle East
    • Africa       
Back to top

Payment Options

Single User : $4175 $3,131
Five User: $5175
$3,881
Enterprise : $9175 $6,881